J&J Innovation Centers report 12 new partners, investments
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Innovation Centers are living up to their promise of supporting early-stage drug, device and consumer product development with 60 investments or partnerships under their collective belt to date, including 12 recently announced transactions.
You may also be interested in...
J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Finding Cutting-Edge Science Takes A Broad Net, J&J Innovation’s Urban Says
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.